What is ABEVMY 100 mg/4 ml
ABEVMY 100 mg/4 ml is a concentrate solution for infusion containing the active ingredient Bevacizumab. Bevacizumab is a monoclonal antibody used as a targeted biological therapy in oncology. It is supplied in a single 4 ml glass vial and administered intravenously under medical supervision.
- ABEVMY is primarily indicated for the treatment of various solid tumors, including metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, glioblastoma, and cervical cancer.
- It works as an anti-angiogenic agent by inhibiting the formation of new blood vessels that tumors require for growth and metastasis.
- As a biologic therapy, it is often combined with chemotherapy or other anticancer agents to improve therapeutic outcomes.
- The medication is used in adults and must be administered in specialized clinical settings due to its potent effects and potential side effects.
- ABEVMY represents an advanced cancer treatment option that specifically targets the tumor microenvironment rather than the tumor cells directly.
Overall, ABEVMY 100 mg/4 ml is a vital tool in the management of several aggressive cancers, offering improved survival rates when used appropriately.
How to use ABEVMY 100 mg/4 ml
Proper administration of ABEVMY is crucial for maximizing efficacy and minimizing adverse effects. The following points guide its use:
- Preparation: The vial must be diluted before infusion, typically in 0.9% sodium chloride or 5% dextrose solution according to the manufacturer’s instructions.
- Administration Route: Administer intravenously via infusion using an infusion pump to control the rate.
- Infusion Rate: The initial infusion is generally given over 90 minutes; if tolerated, subsequent infusions may be shortened to 30-60 minutes.
- Frequency: Usually administered every 2 or 3 weeks depending on the cancer type and treatment protocol.
- Pre-medication: Premedication is generally not required but may be used to prevent infusion-related reactions in some patients.
- Monitoring: Continuous monitoring during infusion for signs of hypersensitivity, hypertension, or other acute reactions is essential.
- Combination Therapy: Often given with chemotherapy; coordination with oncologists is necessary to manage schedules and interactions.
Only trained healthcare professionals should prepare and administer ABEVMY to ensure patient safety.
Mode of Action ABEVMY 100 mg/4 ml
ABEVMY contains Bevacizumab, a recombinant humanized monoclonal antibody with a specific mechanism targeting tumor angiogenesis:
- VEGF Inhibition: Bevacizumab binds to vascular endothelial growth factor A (VEGF-A), a protein essential for angiogenesis (the growth of new blood vessels).
- Blocking Blood Vessel Formation: By neutralizing VEGF-A, ABEVMY prevents VEGF from interacting with its receptors (VEGFR-1 and VEGFR-2) on endothelial cells.
- Starving Tumors: Without new blood vessels, tumors receive less oxygen and nutrients, which inhibits their growth and reduces metastatic potential.
- Normalization of Vasculature: In some cases, ABEVMY may transiently normalize abnormal tumor blood vessels, improving delivery of chemotherapy agents.
- Specificity: The targeted action on VEGF-A spares most normal tissues, reducing systemic toxicity compared to traditional chemotherapy.
This anti-angiogenic mode of action forms the basis for ABEVMY’s effectiveness in controlling tumor progression.
ABEVMY 100 mg/4 ml Interactions ABEVMY 100 mg/4 ml
Drug interactions with ABEVMY must be carefully considered to avoid enhanced toxicity or reduced effectiveness:
- Chemotherapy Agents: Often combined with agents like fluorouracil, irinotecan, paclitaxel, or carboplatin. Close monitoring is required due to overlapping toxicities such as myelosuppression and hypertension.
- Anticoagulants: Bevacizumab can increase the risk of bleeding; co-administration with warfarin or other blood thinners necessitates careful INR and bleeding risk assessment.
- Anti-hypertensive Drugs: ABEVMY may cause or exacerbate hypertension, potentially requiring adjustments in antihypertensive therapy.
- NSAIDs and Corticosteroids: These may affect platelet function and bleeding risk when used concurrently.
- Live Vaccines: Use with caution as ABEVMY can impair wound healing and immune response.
- Other Targeted Therapies: Concomitant use with other VEGF inhibitors or anti-angiogenic agents is generally avoided due to increased risk of adverse events.
Always inform the healthcare team of all medications, supplements, and herbal products before starting therapy.
Dosage of ABEVMY 100 mg/4 ml
The dosage of ABEVMY varies based on the type of cancer, patient condition, and treatment protocol:
- Typical Dose: The most common dose is 5 mg/kg or 10 mg/kg body weight administered every 2 or 3 weeks intravenously.
- Infusion Volume: The drug is diluted to appropriate volume before infusion (e.g., 100 ml or more of saline).
- Adjustments: Dose adjustments may be required in patients with renal or hepatic impairment or based on toxicity profile.
- Duration: Treatment duration depends on clinical response, tolerance, and cancer type; therapy may continue until disease progression or unacceptable toxicity.
- Special Populations: Use in elderly patients requires caution and monitoring; pediatric use is limited and based on specialist advice.
- Missed Dose: Administer as soon as possible and adjust the schedule accordingly; do not double doses.
Only oncology specialists should determine and supervise the exact dosing regimen.
Possible side effects of ABEVMY 100 mg/4 ml
ABEVMY can cause a range of side effects; patients should be closely monitored for these adverse reactions:
- Common Side Effects: Hypertension, fatigue, headache, proteinuria, nosebleeds, and diarrhea.
- Serious Side Effects: Gastrointestinal perforation, hemorrhage, arterial thromboembolic events (e.g., stroke, heart attack), wound healing complications, and severe infusion reactions.
- Infusion Reactions: Fever, chills, rash, or breathing difficulties during or shortly after infusion.
- Infections: Increased susceptibility to infections due to immunomodulation.
- Hypersensitivity: Allergic reactions ranging from mild rash to anaphylaxis.
- Kidney Effects: Proteinuria and potential renal impairment.
- Others: Abdominal pain, weight loss, hypertension-related complications.
Prompt reporting of side effects to healthcare providers is essential to manage risks effectively.
ABEVMY 100 mg/4 ml Contraindications ABEVMY 100 mg/4 ml
ABEVMY should not be used in the following conditions:
- Known hypersensitivity to Bevacizumab or any component of the formulation.
- Patients with recent history of significant hemorrhage or gastrointestinal perforation.
- Severe uncontrolled hypertension despite optimal medical management.
- Pregnant or breastfeeding women, unless the potential benefit outweighs risks, due to possible fetal harm.
- Patients with severe wound healing disorders or those scheduled for major surgery until wound healing is complete.
- Use with caution in patients with cardiovascular disease due to risk of thromboembolism.
Strict patient evaluation and risk-benefit analysis should precede therapy initiation.
Storage of ABEVMY 100 mg/4 ml
Proper storage of ABEVMY ensures its stability and safety:
- Store the unopened vial refrigerated at 2°C to 8°C (36°F to 46°F).
- Do not freeze the product; freezing can damage the monoclonal antibody.
- Protect from light by keeping the vial in the outer carton until use.
- After dilution, use the infusion solution promptly; do not store diluted solutions for more than 24 hours under recommended conditions.
- Keep out of reach of children and unauthorized personnel.
Adhering to storage recommendations maintains drug efficacy and patient safety.
ABEVMY 100 mg/4 ml features an exceptional active ingredient renowned for its potent effects, comprising Bevacizumab. This powerful formulation provides a superior solution for addressing diverse health concerns. With 25 mg/ml concentration and an easily manageable Concentrate for solution for infusion, it remains a preferred option for countless individuals seeking effective treatment.
Introduction
All you need to know about ABEVMY 100 mg/4 ml .
Welcome to Dwaey, specifically on ABEVMY 100 mg/4 ml page.
This medicine contains an important and useful components, as it consists of Bevacizumab.
ABEVMY 100 mg/4 ml is available in the market in concentration 25 mg/ml and in the form of Concentrate for solution for infusion.
MYLAN IRE HEALTHCARE LIMITED is the producer of ABEVMY 100 mg/4 ml and it is imported from IRELAND,
The most popular alternatives of ABEVMY 100 mg/4 ml are listed downward .
-
Active Substance
-
Size
-
Indications
-
Type
Concentrate for solution for infusion
-
Company
MYLAN IRE HEALTHCARE LIMITED
Frequently Asked Questions
ABEVMY 100 mg/4 ml should be stored according to the instructions provided by MYLAN IRE HEALTHCARE LIMITED.
In general, it is recommended to store ABEVMY 100 mg/4 ml in a cool, dry place, away from direct sunlight
and out of the reach of children.
The duration of treatment with ABEVMY 100 mg/4 ml may vary depending on the condition being treated
and the guidance of your healthcare provider. It is important to follow the prescribed treatment
plan and continue taking ABEVMY 100 mg/4 ml for the recommended duration, even if your symptoms improve.
If you have any concerns or questions about the duration of treatment, consult your healthcare provider.
It is important to check with your healthcare provider or read the medication label for specific
instructions regarding alcohol consumption while taking ABEVMY 100 mg/4 ml . Some medications, including
ABEVMY 100 mg/4 ml , may have interactions with alcohol that can reduce effectiveness, increase side
effects, or pose other risks to your health. It is best to follow the guidance provided by your
healthcare professional.
If you miss a dose of ABEVMY 100 mg/4 ml , take it as soon as you remember. However, if it is close
to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing
schedule. Do not take a double dose to make up for a missed one unless advised by your healthcare provider.
No, do not stop taking ABEVMY 100 mg/4 ml without consulting your healthcare provider, even if your
symptoms improve. It is important to complete the full course of treatment as prescribed. Stopping
the medication prematurely may lead to a relapse or incomplete resolution of the condition. If you
have concerns about the duration of treatment, consult your healthcare provider for guidance.
It is important to consult your healthcare provider before taking ABEVMY 100 mg/4 ml if you are
pregnant or breastfeeding. They will be able to assess the potential risks and benefits based on your
specific situation. Please note that the safety and suitability of ABEVMY 100 mg/4 ml during pregnancy
or breastfeeding may depend on the active substance [Active Substance], concentration 25 mg/ml,
and the specific recommendations of MYLAN IRE HEALTHCARE LIMITED.
The effects of ABEVMY 100 mg/4 ml on your ability to drive or operate machinery can vary depending on
the active substance [Active Substance], concentration 25 mg/ml, and individual factors.
Some medications may cause drowsiness, dizziness, or other side effects that can impair your judgment
or coordination. It is important to read the medication label or consult your healthcare provider to
understand any potential effects on your ability to perform tasks that require alertness.
The instructions for taking ABEVMY 100 mg/4 ml with or without food may vary depending on the medication
and the recommendations of MYLAN IRE HEALTHCARE LIMITED. Some medications may be more effective when taken with
food to enhance absorption or reduce stomach irritation, while others may need to be taken on an empty
stomach for optimal absorption. Read the medication label or consult your healthcare provider for specific instructions.
The use of ABEVMY 100 mg/4 ml in children or elderly individuals may depend on various factors, including
the specific medication, type Concentrate for solution for infusion, and the recommendations of MYLAN IRE HEALTHCARE LIMITED. Some
medications may have specific dosing instructions or precautions for these age groups. Consult your
healthcare provider or read the medication label for information regarding the safe and appropriate use
of ABEVMY 100 mg/4 ml in children or elderly individuals.
Dwaey
All medical information published on the Dwaey website aims to increase medical awareness and health education among users. However, it is not a substitute for professional medical advice. Always consult with a specialist doctor. We strongly advise against using any information or medicine found on the site without referring to your healthcare provider.
Related Products
0 Comments